



Published in final edited form as:

*Sci Transl Med.* 2016 November 09; 8(364): 364ra151. doi:10.1126/scitranslmed.aag2367.

## Aggregate penetrance of genomic variants for actionable disorders in European and African Americans

Pradeep Natarajan<sup>1,2,3,\*</sup>, Nina B. Gold<sup>2,4,\*</sup>, Alexander G. Bick<sup>2,3,5,\*</sup>, Heather McLaughlin<sup>2,6,7</sup>, Peter Kraft<sup>8</sup>, Heidi L. Rehm<sup>2,6,7</sup>, Gina M. Peloso<sup>2,3</sup>, James G. Wilson<sup>9</sup>, Adolfo Correa<sup>10</sup>, Jonathan G. Seidman<sup>2,5</sup>, Christine E. Seidman<sup>2,5,11,12</sup>, Sekar Kathiresan<sup>1,2,3,†</sup>, and Robert C. Green<sup>2,3,7,11,‡</sup>

<sup>1</sup>Center for Human Genetic Research, Cardiovascular Research Center, and Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

<sup>2</sup>Harvard Medical School, Boston, MA 02115, USA

<sup>3</sup>Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA

<sup>4</sup>Boston Children's Hospital, Boston, MA 02115, USA

<sup>5</sup>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA

<sup>6</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

<sup>7</sup>Partners HealthCare Personalized Medicine, Boston, MA 02115, USA

<sup>8</sup>Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

<sup>9</sup>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA

<sup>10</sup>Departments of Pediatrics and Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA

<sup>11</sup>Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA

<sup>12</sup>Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA

exclusive licensee American Association for the Advancement of Science.

<sup>‡</sup>Corresponding author. rcgreen@bwh.harvard.edu.

\*These authors contributed equally to this work.

†These authors contributed equally to this work.

### SUPPLEMENTARY MATERIALS

[www.sciencetranslationalmedicine.org/cgi/content/full/8/364/364ra151/DC1](http://www.sciencetranslationalmedicine.org/cgi/content/full/8/364/364ra151/DC1)

**Author contributions:** All authors participated in the design or interpretation of the reported results, the acquisition of data, and the drafting or revising of the manuscript.

**Competing interests:** R.C.G. has equity in Genome Medical, a company that provides clinical genomics consultation services, and receives compensation for speaking or advisory services to AIA, Helix, Illumina, Invitae, and Prudential. S.K. has been a paid consultant to Regeneron, Celera, Bayer, Catabasis, Merck, Genomics PLC, San Therapeutics, Novartis, Sanofi, Alnylam, Eli Lilly, Leerink Partners, Noble Insights, and AstraZeneca. The remaining authors declare that they have no competing interests.

**Data and materials availability:** The dbGAP accession numbers for the sequences and cardiovascular phenotype data reported in this paper are NHLBI Framingham Cohort (phs000307.v3.p7) and NHLBI JHS (phs000286.v3.p1). All results of secondary data analysis used for this report are available from the authors.

## Abstract

In populations that have not been selected for family history of disease, it is unclear how commonly pathogenic variants (PVs) in disease-associated genes for rare Mendelian conditions are found and how often they are associated with clinical features of these conditions. We conducted independent, prospective analyses of participants in two community-based epidemiological studies to test the hypothesis that persons carrying PVs in any of 56 genes that lead to 24 dominantly inherited, actionable conditions are more likely to exhibit the clinical features of the corresponding diseases than those without PVs. Among 462 European American Framingham Heart Study (FHS) and 3223 African-American Jackson Heart Study (JHS) participants who were exome-sequenced, we identified and classified 642 and 4429 unique variants, respectively, in these 56 genes while blinded to clinical data. In the same participants, we ascertained related clinical features from the participants' clinical history of cancer and most recent echocardiograms, electrocardiograms, and lipid measurements, without knowledge of variant classification. PVs were found in 5 FHS (1.1%) and 31 JHS (1.0%) participants. Carriers of PVs were more likely than expected, on the basis of incidence in noncarriers, to have related clinical features in both FHS (80.0% versus 12.4%) and JHS (26.9% versus 5.4%), yielding standardized incidence ratios of 6.4 [95% confidence interval (CI), 1.7 to 16.5;  $P = 7 \times 10^{-4}$ ] in FHS and 4.7 (95% CI, 1.9 to 9.7;  $P = 3 \times 10^{-4}$ ) in JHS. Individuals unselected for family history who carry PVs in 56 genes for actionable conditions have an increased aggregated risk of developing clinical features associated with the corresponding diseases.

## INTRODUCTION

Clinical exome and genome sequencing is increasingly applied in the practice of medicine, but many challenges remain (1–5). There has been extensive discussion of the merits of selection, ascertainment, and reporting of incidental or secondary findings that come to light during sequencing, especially when they may be of medical value to patients and their families (6–8). In 2013, the American College of Medical Genetics and Genomics (ACMG) recommended that laboratories providing clinical sequencing for any medical indication should search for and report pathogenic variants (PVs) in 56 genes (the ACMG56) that represent 24 rare Mendelian conditions for which there are recommended treatments (7, 9). The ACMG recommendations have generated debate (10, 11), in part because the risk associated with PVs in families with many affected relatives is not always the same for persons whose families are not enriched with affected relatives (12–15), and thus it has been unclear whether in the absence of a family history these variants truly represent an increase in risk.

In addition, large-scale biobanks are being sequenced for research purposes, and investigators are struggling with recent recommendations about whether and how to return genomic findings of potential medical importance to participants and their family members (8, 16). Although the genes and variants to be returned are not specified in these recommendations, the ACMG56 have become a convenient starting point for these discussions and for the generation of lists of genes that are actually being reported to the participants. For example, information about the ACMG56, with some modifications, is being returned to the participants by some sites within the eMERGE III (Electronic Medical

Records and Genomics Phase III) network (17), as well as the Geisinger MyCode research project (18). These research initiatives presage the use of genome sequencing for population screening and raise the issue of whether this is appropriate (19–23).

Estimating the association between specific PVs in individual genes for rare Mendelian conditions and clinical phenotypes in an unselected population is challenging because PVs associated with Mendelian diseases are rare, variants are difficult to categorize with confidence, even among experts (24), and clinical phenotypes unrelated to known genetic changes are relatively common in the general population. Because most of what we know in genetics has been from patients presenting to specialized clinics, and there have been few population-based estimates of variant penetrance, it is surprisingly difficult to demonstrate the seemingly straightforward idea that unselected persons carrying PVs in a group of genes known to be associated with disease are actually at increased risk for those conditions or to estimate the effect size of this increased risk. To address this, we devised an unbiased method to prospectively examine the aggregate association between PVs in a set of genes and clinical features among research participants from the Framingham Heart Study (FHS) and, separately, in the Jackson Heart Study (JHS), all of whom had been exome-sequenced and systematically phenotyped. In these two independent populations, we tested the hypothesis that participants with PVs in any of the ACMG56 genes were more likely to exhibit related clinical features (RCFs) than would be expected in participants without a PV.

## RESULTS

### Participant description

The FHS participants were drawn from the FHS Offspring cohort [ $n = 290$ , 35.7% female; mean age at enrollment, 36.8 (SD, 9.3) years] and the FHS Generation 3 cohort ( $n = 172$ , 35.7% female; mean age at enrollment, 44.5 (SD, 8.9) years). All FHS participants were European American, and comprehensive clinical phenotypes were gleaned from the most recent clinical examination. The participants in the FHS cohort were followed for an average of 20.4 (SD, 14.3) years. Among the 3223 JHS participants, all were African-American, 62.4% were female, and mean age at enrollment was 55.6 (SD, 12.8) years. The JHS participants are being followed longitudinally, but comprehensive clinical phenotypes were only available from the baseline examination.

### Overview of study design and phenotype characterization

We designed a procedure for unbiased analysis of the association between exome sequencing and phenotype data from 462 participants in the FHS and 3223 participants in the JHS. Family history was not considered in selecting participants for enrollment in either cohort, nor was it considered in the selection of participants for sequencing. Without knowledge of the phenotypes, we classified all variants in the ACMG56 genes, using a previously described multistep algorithm (25, 26) and following recently revised ACMG variant classification recommendations (27). We tabulated RCFs (Table 1) corresponding to the 24 disease conditions associated with the ACMG56 from clinical records of the FHS and JHS participants while blinded to the results of sequencing.

## Variant classification

By analyzing exomes, we identified 642 unique variants within the ACMG56 genes in the 462 FHS participants and 4429 unique variants in the 3223 JHS participants, and then subsequently classified these while blinded to the phenotype information (see Materials and Methods). Among FHS participants, we identified five PVs in five individuals (1.1% of the FHS cohort) and two likely PVs (LPVs) in two individuals (0.4% of the FHS cohort). Among JHS participants, we identified 19 PVs in 31 individuals (1.0% of the JHS cohort) and 4 LPVs in 4 individuals (0.1% of the JHS cohort). A description of the variants classified as PVs and LPVs, along with the presence or absence of clinical features suggestive of the corresponding diseases, is shown in Table 2 for the FHS participants and Table 3 for the JHS participants. A listing of the specific transcripts that corresponded to the sequenced genes is shown in table S1, and the evidence from the literature that we used to classify variants into PVs and LPVs from FHS and JHS participants is described in table S2. Variants of uncertain significance (VUSs) in the ACMG56 were identified in 146 FHS participants (31.6%) and 917 JHS participants (28.5%). The ACMG guidelines do not recommend returning VUSs, so these were excluded from further analysis.

## Comparison of observed and expected proportions of phenotypes

To examine our primary hypothesis, we tested whether carriers of PVs in any of the ACMG56 genes were more likely to exhibit corresponding RCFs than would be expected in participants without a PV. We compared the observed number of RCFs in individuals with any PV to the expected number, assuming that the fraction of carriers of particular PVs who exhibited an RCF was equal to the fraction of noncarriers exhibiting those RCFs (see Materials and Methods). Of five FHS participants with PVs, four displayed an RCF, and this proportion (80%) was higher than expected (12.4%; one-sided binomial mixture test,  $P = 7 \times 10^{-4}$ ). The standardized incidence ratio (SIR), which is the ratio of observed RCFs among those with PVs to the number expected on the basis of incidence rates among those without PVs, was 6.4 in the FHS [95% confidence interval (CI), 1.7 to 16.5]. Of 26 JHS participants with PVs, 7 displayed an RCF, and this proportion (26.9%) was also higher than expected (5.4%;  $P = 3 \times 10^{-4}$ ), corresponding to an SIR of 4.7 (95% CI, 1.9 to 9.7). The addition of LPV carriers to this analysis to estimate SIR for PVs and LPVs together yielded similar results [SIR, 4.9; 95% CI, 1.3 to 12.6 in FHS ( $P = 0.004$ ) and SIR, 4.3; 95% CI, 1.8 to 8.4 in JHS ( $P = 2 \times 10^{-4}$ )]. Preplanned secondary analyses of individuals with cancer and cardiovascular diseases revealed that the incidence of RCFs was also significantly higher than expected for carriers of PVs associated with cancer and cardiovascular diseases (Table 4).

## Description of individuals carrying PVs

In the FHS, a participant with an *LDLR* nonsense variant (p.Cys143\*) had an untreated low-density lipoprotein (LDL) cholesterol level of 195 mg/dl (optimal <130 mg/dl). Notably, this individual was selected for sequencing in a hypertension study and thus was not selected for sequencing on the basis of her lipid status. A participant with a pathogenic missense variant in *MYBPC3* (p.Arg502Trp) had manifestations of dilated cardiomyopathy. Two participants with two different *BRCA2* frameshift variants (p.Leu1466Phefs\*2 and p.Thr1738Ilefs\*2)

had (respectively) grade 3 (poorly differentiated), Gleason score 5 prostate cancer diagnosed at age 78 and ductal carcinoma in situ breast cancer at age 55. Neither of the individuals carrying LPVs had RCFs. No PV or LPV carrier was a first-degree relative of another carrier.

In the JHS, there were three individuals who had PVs in cancer predisposition genes who reported a history of cancer, although the type of cancer was not recorded. An individual with a *BRCA2* frameshift mutation (p.Val220Ilefs\*2) was diagnosed with cancer at age 60. A carrier of *MLH1* p.Arg687Trp was diagnosed with cancer at age 36. A carrier of *TP53* p.Arg273His, who was enrolled at age 93, reported a diagnosis of cancer at age 89. A carrier of *MYH7* p.Ala797Thr had left ventricular hypertrophy with an interventricular septal thickness of 13.2 mm and posterior wall thickness of 12.8 mm (normal, <11 mm). Carriers of *KCNQ1* p.Arg518\* and *KCNQ1* p.Val205Met had corrected QT (QTc) intervals of 477 and 494 ms [normal, <440 ms in men and <460 ms in women]. Furthermore, a carrier of the LPV *KCNQ1* p.Gly179Ser had a QTc interval of 506 ms. A participant with *LDLR* p.Pro685Leu had a markedly elevated untreated LDL cholesterol level (357.5 mg/dl; optimal, <130 mg/dl). One family of six, and two additional pairs of first-degree relatives each harbored the same PV, but none of these 10 individuals displayed an RCF, and thus familial presence of the same variant did not inflate the observed association.

## DISCUSSION

In genetics, penetrance is the proportion of individuals harboring a particular variant who exhibit, or eventually exhibit, the associated disease (28). Estimating the penetrance of PVs in populations that are not enriched for family history is a challenge because specific PVs in any given gene are rare, and therefore an exceedingly large population would need to be systematically examined over many years to ascertain accurate phenotype information, which could emerge at any time in the lifetime of the individual. Our analyses do not address the penetrance of specific variants within individual genes. Instead, we tested whether pathogenic variants in a set of genes are collectively associated with RCFs for those conditions, and, if so, what is the effect size of this aggregated association. To answer this question, we conducted two separate, prospective, hypothesis-driven analyses of 462 European Americans and 3223 African-Americans for a group of 56 genes associated with disease conditions where early intervention could lead to prevention or better outcomes. We found that persons carrying PVs in a subset of these 56 genes demonstrate an increased aggregate risk of having clinical features associated with that gene in both the FHS (an entirely European American population) and JHS (an entirely African-American population). The difference in percentages of the cohort with the phenotypes of interest may be due to an enhanced healthy volunteer effect among the JHS cohort or to the fact that phenotypes were collected prospectively over several examinations spanning the course of decades in FHS but were based on a single examination thus far in JHS.

The frequencies we found for PVs and LPVs in the FHS and JHS populations are similar to recent assessments of PVs in medically actionable genes among large collections of individuals with exome sequences (29, 30) and to others who have reported variants in the ACMG56 among collections of exomes or genomes (31, 32). As in these reports, most of the

PVs described here are predicted to encode null alleles and result in haploinsufficiency, a well-defined mechanism of pathogenicity for most genetic diseases. The range of frequencies for PVs in these other studies (from 0.8 to ~5%) could reflect differences in how the various populations were identified and recruited, but more likely reflect variability in variant classification. As we have demonstrated (24), even expert laboratories struggle to achieve complete concordance in variant classification. These issues reinforce the need to apply rigorous standards for variant classification and to share variant classification through mechanisms such as ClinGen (33), and also underscore the methodological importance of blinded variant classification in these analyses.

Understanding the association between PVs and RCFs in the general population is necessary for the informed use of genomics to evaluate patients for secondary findings (sometimes characterized as opportunistic screening) and for the use of sequencing in asymptomatic individuals (population screening) (19, 34, 35), but data to support or refute these practices are scarce. In a separate study of FHS participants, 21% of individuals with PVs in hypertrophic cardiomyopathy genes had clinical features suggestive of cardiomyopathy, a lower proportion than expected in multiplex families but a higher proportion than in persons without such variants (36). Specific founder mutations for long QT syndrome among the Finnish population are far from fully penetrant but are still highly associated with prolongation of QT interval in the relatively homogeneous Finnish population (37). However, analyses of medical records for evidence of cardiac arrhythmias did not demonstrate detectable penetrance of PVs in arrhythmia-related genes, perhaps because variant classification was suboptimal (38, 39). Screening for Lynch syndrome has been piloted among incident cases of colorectal cancer (40) but not among cancer-free individuals. A substantially increased risk for breast cancer associated with *BRCA* variants has recently been demonstrated (41), prompting a call for population-based screening of women around the age of 30 (42). For other genes and variants that are highly penetrant in multiplex families, an increased likelihood of clinical features among carriers cannot always be demonstrated in the general population: Individuals with well-established PVs for mature-onset diabetes of the young in the FHS and JHS do not exhibit an increased likelihood of having type 2 diabetes or impaired fasting glucose (43). Thus, the literature contains mixed results as to whether PVs in some genes, even some of the genes included among the ACMG56, individually confer increased risk of disease in populations that are not selected for family history.

Estimations of gene-disease association are traditionally conceptualized as penetrance on a gene-by-gene and variant-by-variant basis, and predicting the likelihood of a phenotype from a particular variant in a particular gene is difficult when disease prevalence is low and carrier status prevalence is rare. However, there may be value in aggregating PVs across a number of genes to consider the prior probability as a compound hypothesis relating to numerous diseases. For example, among 951 individuals exome-sequenced as part of the ClinSeq cohort, 103 (10.8%) had putative loss-of-function variants in a large number of genes likely to cause a phenotype in heterozygotes (44). In ClinSeq, intensive targeted phenotyping of 79 of these individuals revealed 34 (43%) with personal or family histories that could be attributed to that gene. That analysis deliberately started with the PVs among a population recruited in part for cardiovascular risk and then searched for the corresponding

phenotype in that participant or the participant's family, often uncovering evidence of a previously unrecognized but non-life-threatening genetic condition. In our analyses, we approached both variant classification and the tabulation of RCFs independently and blinded to each other and examined their association in a subset of genes that have been linked to life-threatening conditions in which early intervention or surveillance could potentially mitigate risk.

Our study has several important limitations. These analyses only examined the aggregate association of PVs with RCFs from the corresponding conditions but did not address the penetrance of individual variants or PVs within a specific gene, because this would have required vastly larger sample sizes. Although the FHS and JHS participants were neither enrolled nor sequenced on the basis of family history, the selection of participants for exome sequencing in FHS was based on their involvement in other studies and may therefore not be representative of the entire FHS population. This was not the case in the JHS where all consenting participants with available DNA were exome-sequenced. Our variant classification strategy may have missed some disease-associated variants by dismissing novel missense variants of unknown function from consideration (45). The a priori definition of both observed and expected RCFs in our analysis included any cancer, thus the cancers associated with PVs and the cancers counted in the comparison populations were appropriately included; however, had cancer cases been considered RCFs only when they had an onset early in life, the differences between the observed and expected penetrance of this group of variants might have been different. It is possible that some of the identified PVs occurred in multiplex families, although none of the participants were selected for sequencing based on family history. In JHS, a family of six individuals carried *PKP2* p.Arg413\*, a PV expected to result in arrhythmogenic right ventricular dysplasia, but none of the family members displayed features of right ventricular abnormalities by echocardiography; therefore, the observed association was not inflated. The number of individuals with LPVs was too small to independently analyze this group, but adding PVs and LPVs together did not change the strength or significance of the association within each population.

These limitations are balanced by a number of strengths. The FHS and JHS cohorts are exceptionally well-studied populations where both sequence data and high-quality clinical data, including electrocardiograms, echocardiograms, and lipid levels, were available for all participants, not just those who had been recognized by the medical care system as patients. Aside from 25 FHS participants who were selected for sequencing on the basis of elevated LDL cholesterol, none of the participants were selected for sequencing on the basis of phenotypes examined in our analysis, and none of those identified in Table 2 with lipid abnormalities were from those 25 individuals. In addition, we pre-specified our hypothesis and compared PVs and RCFs that were ascertained and classified independently of each other. Any misclassifications of variants, or censoring of phenotypes due to participant dropout or death, would be expected to bias the results toward the null. Performing these analyses in cohorts where all participants undergo phenotyping is advantageous, but even such systematic testing may incompletely capture some RCFs, such as right ventricular abnormalities on echocardiography for arrhythmogenic right ventricular dysplasia, limiting the ability to detect phenotypes and further biasing toward the null. The relatively few

individuals with PVs in the ACMG56 is reflected in a wide CI for the analysis of each cohort; nevertheless, despite the small numbers and limited power, the associations range from a lower bound that is moderately strong to an upper bound that is extremely strong. Although aggregating that the exposure improves power, the combined carrier rate is low in a sample size of 3685, thereby limiting effect estimate precision. However, offsetting this issue is the fact that we independently demonstrated association in two ethnically distinct cohorts with similar relative effect estimates.

The ACMG recommendations for the return of secondary findings were expressly formulated for use in clinical sequencing (7). However, other groups have recommended the return of genomic variants that have medical actionability in research participants who request such information (8, 46), and the ACMG recommendations for clinical sequencing have been suggested as a basis for selecting the appropriate list of genes and category of variant (47). As large-scale, hospital-based, national biobanks begin to generate genomic data, and research initiatives like the Precision Medicine Initiative affirm the right of research participants to have access to their research results (48), guidance regarding the management of such findings is urgently needed. It is important to note that it has not been demonstrated that detecting such variants actually results in improved health outcomes, and to many, the absence of this evidence remains a compelling objection to both opportunistic and population screening. Our results should be replicated in other populations that are followed for clinical outcomes and should be interpreted with caution, but may help inform the emerging debate about whether and how to offer the return of individual genomic results to participants in research cohorts and biobanks, as well as in clinical sequencing.

## MATERIALS AND METHODS

### Study design

We designed and carried out two independent analyses to estimate the association between PVs derived from exome sequencing in any of 56 genes and clinical features related to the actionable Mendelian conditions that have been linked to these genes. We examined all of the participants who had been sequenced at the time of the analysis in FHS and JHS, and used systematically collected phenotype information from each. Variants were classified as described below without knowledge of the clinical phenotypes, and phenotypes were assessed without knowledge of the variants. The association was estimated within each cohort independently, providing replication of the results.

### Participants

The FHS is a multigenerational, longitudinal study of European Americans established in 1948 in Framingham, MA. Participants in this analysis were from FHS Offspring (children and spouses of the Original cohort) and Generation 3 (children of the Offspring) cohorts (49, 50). Offspring participants were examined every 4 to 8 years, for a total of eight exams. Generation 3 participants were examined twice. The JHS is a prospective, longitudinal study of African-Americans established in 1998 in Jackson, MS. The details of the cohort, including sampling, recruitment, and examinations, have been previously described (51–53).



For the FHS, as part of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP), FHS Offspring and Generation 3 participants were selected for exome sequencing as follows: 41 cases and 135 controls for a study of myocardial infarction, 80 cases and 86 controls for a study of blood pressure, 13 cases and 12 controls for a study of LDL cholesterol, 30 cases with stroke, and 65 FHS participants who were randomly selected.

For the JHS, we analyzed genomic and phenotype data from participants who consented to DNA collection during the first examination (2000 to 2004). Exome sequencing was completed for all consenting JHS participants (3273 of the 5301 participants).

These studies were performed using protocols approved by ethics committees at FHS and JHS and by their institutional review boards, with informed consent from all participants.

### Exome sequencing

Exome sequencing, variant detection, and quality control steps for the FHS samples have been previously described (54). Briefly, exome capture used either Agilent SureSelect Human All Exon v2 kit (55), or Roche/NimbleGen SeqCap EZ Human Exome Library v1.0 (~32 Mb; Roche NimbleGen EZ Cap v1) or EZ Cap v2 (~34 Mb). Enriched exome libraries were sequenced on an Illumina GAIIX or HiSeq 2000, aligned to human reference (GRCh37) using BWA (56), followed by duplicate removal, indel realignment, base quality score recalibration, and variant detection using Genome Analysis Toolkit (57).

### Variant classification

Variants were adjudicated independently by two evaluators who made their classifications without any knowledge of the phenotype data and any differences resolved by consultation with a third evaluator. Variant classification was completed using a multistep algorithm as described (25, 26, 45) and was consistent with both the ACMG recommendation for secondary findings (7) and the more recently developed ACMG recommendations for variant classification (27).

Transcripts for analysis were those previously selected by the Partners HealthCare Laboratory for Molecular Medicine, a CLIA-certified molecular diagnostic laboratory, and were typically the longest (see table S1). Copy number variants were not evaluated because of the diversity of capture methods and sequencing platforms used for this data set. For variant classification, Alamut (Interactive Biosoftware) (58) and Variant Effect Predictor (59) were used to aggregate variant annotations from multiple sources, including transcript information and evolutionary conservation from the University of California Santa Cruz genome browser (60), and minor allele frequency from the ESP [Exome Variant Server, NHLBI ESP, Seattle, WA (<http://evs.gs.washington.edu/EVS/>), 15 December 2011] database, 1000 Genomes Project (<http://browser.1000genomes.org/>), and Exome Aggregation Consortium (<http://exac.broadinstitute.org/>) browsers. Previously published variants were identified by filtering against the Human Gene Mutation Database (HGMD) Professional (61), GeneInsight (62), and ClinVar (63) databases, the latter two databases were also used in variant classification to obtain additional unpublished data on HGMD-selected variants.

Only missense variants that had previously been reported in an index case, denoted as “disease mutations” in the HGMD nomenclature or classified as pathogenic by at least one clinical laboratory in ClinVar, as well as nonsense, frameshift, and splice variants, were considered. Variants previously reported only in the context of functional or in silico experiments, but not previously associated with a symptomatic individual, were not further considered.

Variants were classified as PV if, in addition to being absent or at a frequency in population databases not inconsistent with their disease penetrance: (i) They were protein-truncating variants (nonsense, frameshift, or  $\pm 1,2$  splice) in a gene where loss of function is a well-established disease mechanism, and the variant was expected to result in nonsense-mediated decay; (ii) literature review identified significant segregation with disease (defined as 10 meioses); or (iii) literature review identified moderate segregation with disease (5 to 9 meioses), and the amino acid was conserved in at least mammals and birds, or the impact of the variant was supported by strong functional data. Variants were classified as an LPV if, in addition to being absent or at a frequency in population databases not inconsistent with their disease penetrance: (i) Literature review showed moderate segregation (5 to 9 meioses) with disease, the amino acid was conserved in all mammals and birds, but functional data were either limited or absent; (ii) literature review identified minimal familial segregation ( $<5$  meioses), but the amino acid was both conserved in all mammals and supported by strong functional data; or (iii) they were protein-truncating variants (nonsense, frameshift, or  $\pm 1,2$  splice) in a gene where loss-of-function variants have been observed but was not yet a well-established disease mechanism, and the variant was expected to result in nonsense-mediated decay. Variants were classified as benign if the frequency of the variant was above 0.3% for variants associated with dominantly inherited diseases. All other variants were classified as VUS.

For secondary analyses, we grouped the ACMG genes into 23 that are cancer-related (*APC*, *BRCA1*, *BRCA2*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF2*, *PMS2*, *PTEN*, *RB1*, *RET*, *SDHD*, *SDHAF2*, *SDHB*, *SDHC*, *STK11*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1*) and 31 that are cardiovascular-related (*ACTC1*, *GLA*, *LMNA*, *MYBPC3*, *MYH7*, *MYL2*, *MYL3*, *PRKAG2*, *TNNT2*, *TNNI3*, *TPM1*, *DSC2*, *DSG2*, *DSP*, *PKP2*, *TMEM43*, *KCNH2*, *KCNQ1*, *SCN5A*, *RYR2*, *ACTA2*, *COL3A1*, *FBN1*, *MYLK*, *MYH11*, *SMAD3*, *TGFBR1*, *TGFBR2*, *APOB*, *LDLR*, and *PCSK9*). Two genes conferring susceptibility to malignant hyperthermia (*CACNA1S* and *RYR1*) were not considered in the secondary analyses.

### Phenotype data

FHS phenotypes were downloaded from the database of Genotypes and Phenotypes (dbGaP) and were available throughout the period of follow-up, whereas JHS phenotypes were only available from Exam 1 and were extracted from the JHS Vanguard Center package for Exam 1 (53). Sex, age, and date of examination for each subject were derived from data recorded during clinical examinations. RCFs for diseases corresponding with the ACMG genes were ascertained and tabulated without knowledge of the genetic data. For cancer, an aggregated FHS cancer database, with subject diagnoses confirmed from pathology reports and clinical notes, was queried (64, 65), whereas cancer diagnoses in JHS were extracted from Exam 1

participant surveys. For both data sets, any history of cancer was recorded regardless of the age of onset of the cancer. For cardiovascular diseases, the most recent lipid levels, echocardiography, and electrocardiogram data were recorded and categorized according to prespecified criteria (Table 1). In both FHS and JHS, phenotypic data sets were highly complete with less than 4% of participants having missing data for any phenotypic variable.

### Statistical analyses

We calculated the expected number of RCFs among those with PVs as  $\sum_i n_i \pi_i$ , where  $n_i$  is the number of individuals with a PV in class  $i$  (cancer, hypertrophic and dilated cardiomyopathy, arrhythmogenic right ventricular dysplasia/cardiomyopathy, and dyslipidemia), and  $\pi_i$  is the fraction of individuals without PVs exhibiting an RCF in class  $i$ . In the FHS cohort, we selected individuals with breast, ovarian, prostate, and gastrointestinal cancer, whereas in the JHS, cancer subtypes were not available, so we used any history of cancer. We estimated statistical significance through simulation: We sampled a binomial random variable with size  $n_i$  and probability  $\pi_i$  for each class  $i$  and summed these five random variables (generating a mixture of binomials). We generated 100,000 replicates of this simulated RCF count and estimated the (one-sided)  $P$  value as the proportion of replicates where the simulated count was equal to, or exceeded, the observed count. Second, we repeated this procedure for cancer and cardiovascular PVs. We also calculated SIR as the ratio of the observed RCF count to the expected count (66). All statistical analyses were performed with R (version 3.0.2).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

We thank A. Cupples, S. Gray, M. Lebo, and K. Rothman for helpful comments on earlier versions of the manuscript.

**Funding:** This work was supported by NIH grants U01HG006500, U19HD077671, U41HG006834, T32GM007753, R01CA154517, and R01HG06615, and the Howard Hughes Medical Institute. The FHS was supported by contracts N01HC25195 and 6R01NS17950 from NHLBI. The JHS was supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, and HHSN268201300050C from NHLBI and the National Institute on Minority Health and Health Disparities.

### REFERENCES AND NOTES

1. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. *N Engl J Med.* 2014; 370:2418–2425. [PubMed: 24941179]
2. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, Ward P, Braxton A, Wang M, Buhay C, Veeraraghavan N, Hawes A, Chiang T, Leduc M, Beuten J, Zhang J, He W, Scull J, Willis A, Landsverk M, Craigen WJ, Bekheirnia MR, Stray-Pedersen A, Liu P, Wen S, Alcaraz W, Cui H, Walkiewicz M, Reid J, Bainbridge M, Patel A, Boerwinkle E, Beaudet AL, Lupski JR, Plon SE, Gibbs RA, Eng CM. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA.* 2014; 312:1870–1879. [PubMed: 25326635]
3. Green RC, Goddard KAB, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne

- PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH, CSER Consortium. Clinical Sequencing Exploratory Research Consortium. Accelerating evidence-based practice of genomic medicine. *Am J Hum Genet.* 2016; 98:1051–1066. [PubMed: 27181682]
4. Delaney SK, Hultner ML, Jacob HJ, Ledbetter DH, McCarthy JJ, Ball M, Beckman KB, Belmont JW, Bloss CS, Christman MF, Cosgrove A, Damiani SA, Danis T, Delledonne M, Dougherty MJ, Dudley JT, Faucett WA, Friedman JR, Haase DH, Hays TS, Heilsberg S, Huber J, Kaminsky L, Ledbetter N, Lee WH, Levin E, Libiger O, Linderman M, Love RL, Magnus DC, Martland A, McClure SL, Megill SE, Messier H, Nussbaum RL, Palaniappan L, Patay BA, Popovich BW, Quackenbush J, Savant MJ, Su MM, Terry SF, Tucker S, Wong WT, Green RC. Toward clinical genomics in everyday medicine: Perspectives and recommendations. *Expert Rev Mol Diagn.* 2016; 16:521–532. [PubMed: 26810587]
  5. Bowdin S, Gilbert A, Bedoukian E, Carew C, Adam MP, Belmont J, Bernhardt B, Biesecker L, Bjornsson HT, Blitzer M, D'Alessandro LCA, Deardorff MA, Demmer L, Elliott A, Feldman GL, Glass IA, Herman G, Hindorff L, Hisama F, Hudgins L, Innes AM, Jackson L, Jarvik G, Kim R, Korf B, Ledbetter DH, Li M, Liston E, Marshall C, Medne L, Meyn MS, Monfared N, Morton C, Mulvihill JJ, Plon SE, Rehm H, Roberts A, Shuman C, Spinner NB, Stavropoulos DJ, Valverde K, Waggoner DJ, Wilkens A, Cohn RD, Krantz ID. Recommendations for the integration of genomics into clinical practice. *Genet Med.* 2016
  6. Green RC, Berg JS, Berry GT, Biesecker LG, Dimmock DP, Evans JP, Grody WW, Hegde MR, Kalia S, Korf BR, Krantz I, McGuire AL, Miller DT, Murray MF, Nussbaum RL, Plon SE, Rehm HL, Jacob HJ. Exploring concordance and discordance for return of incidental findings from clinical sequencing. *Genet Med.* 2012; 14:405–410. [PubMed: 22422049]
  7. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG. American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med.* 2013; 15:565–574. [PubMed: 23788249]
  8. Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, Cho MK, Christman MF, Green RC, Hall R, Illes J, Keane M, Knoppers BM, Koenig BA, Kohane IS, LeRoy B, Maschke KJ, McGeeveran W, Ossorio P, Parker LS, Petersen GM, Richardson HS, Scott JA, Terry SF, Wilfond BS, Wolf W. Managing incidental findings and research results in genomic research involving biobanks and archived datasets. *Genet Med.* 2012; 14:361–384. [PubMed: 22436882]
  9. ACMG Board of Directors. ACMG policy statement: Updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. *Genet Med.* 2015; 17:68–69. [PubMed: 25356965]
  10. Burke W, Antommaria AHM, Bennett R, Botkin J, Clayton EW, Henderson GE, Holm IA, Jarvik GP, Khoury MJ, Knoppers BM, Press NA, Ross LF, Rothstein MA, Saal H, Uhlmann WR, Wilfond B, Wolf SM, Zimmern R. Recommendations for returning genomic incidental findings?. We need to talk! *Genet Med.* 2013; 15:854–859. [PubMed: 23907645]
  11. Green RC, Lupski JR, Biesecker LG. Reporting genomic sequencing results to ordering clinicians: Incidental, but not exceptional. *JAMA.* 2013; 310:365–366. [PubMed: 23917280]
  12. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. *J Natl Cancer Inst.* 2002; 94:1221–1226. [PubMed: 12189225]
  13. Brunham LR, Hayden MR. Whole-genome sequencing: The new standard of care? *Science.* 2012; 336:1112–1113. [PubMed: 22654044]
  14. Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. *Genet Med.* 2012; 14:399–404. [PubMed: 22323072]
  15. Rahman N. Realizing the promise of cancer predisposition genes. *Nature.* 2014; 505:302–308. [PubMed: 24429628]
  16. Wolf SM, Branum R, Koenig BA, Petersen GM, Berry SA, Beskow LM, Daly MB, Fernandez CV, Green RC, LeRoy BS, Lindor NM, O'Rourke PP, Breitkopf CR, Rothstein MA, Van Ness B,

- Wilfond BS. Returning a research participant's genomic results to relatives: Analysis and recommendations. *J Law Med Ethics*. 2015; 43:440–463. [PubMed: 26479555]
17. National Human Genome Research Institute (NHGRI). The Electronic Medical Records and Genomics (eMERGE) Network, phase III study investigators (U01). NHGRI; 2016. Publication RFA-HG-14-025 <http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-14-025.html>
  18. Carey DJ, Fetterolf SN, Davis FD, Faucett WA, Kirchner HL, Mirshahi U, Murray MF, Smelser DT, Gerhard GS, Ledbetter DH. The Geisinger MyCode community health initiative: An electronic health record-linked biobank for precision medicine research. *Genet Med*. 2016; 18:906–913. [PubMed: 26866580]
  19. Khoury MJ, McCabe LL, McCabe ERB. Population screening in the age of genomic medicine. *N Engl J Med*. 2003; 348:50–58. [PubMed: 12510043]
  20. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. *Genet Med*. 2011; 13:499–504. [PubMed: 21558861]
  21. Hamilton JG, Edwards HM, Khoury MJ, Taplin SH. Cancer screening and genetics: A tale of two paradigms. *Cancer Epidemiol Biomarkers Prev*. 2014; 23:909–916. [PubMed: 24706727]
  22. Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. *Am J Prev Med*. 2016; 50:398–401. [PubMed: 26547538]
  23. Linderman MD, Nielsen DE, Green RC. Personal genome sequencing in ostensibly healthy individuals and the PeopleSeq Consortium. *J Pers Med*. 2016; 6:E14. [PubMed: 27023617]
  24. Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, Berg JS, Biswas S, Bowling KM, Conlin LK, Cooper GM, Dorschner MO, Dulik MC, Ghazani AA, Ghosh R, Green RC, Hart R, Horton C, Johnston JJ, Lebo MS, Milosavljevic A, Ou J, Pak CM, Patel RY, Punj S, Richards CS, Salama J, Strande NT, Yang Y, Plon SE, Biesecker LG, Rehm HL. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am J Hum Genet*. 2016; 98:1067–1076. [PubMed: 27181684]
  25. Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly MA, Pugh TJ, Funke BH, Rehm HL, Lebo MS. A systematic approach to assessing the clinical significance of genetic variants. *Clin Genet*. 2013; 84:453–463. [PubMed: 24033266]
  26. McLaughlin HM, Ceyhan-Birsoy O, Christensen KD, Kohane IS, Krier J, Lane WJ, Lautenbach D, Lebo MS, Machini K, MacRae CA, Azzariti DR, Murray MF, Seidman CE, Vassy JL, Green RC, Rehm HL. MedSeq Project, A systematic approach to the reporting of medically relevant findings from whole genome sequencing. *BMC Med Genet*. 2014; 15:134. [PubMed: 25714468]
  27. Richards S, Aziz N, Bale S, Dick D, Das S, Gastier-Foster J, Grody WW, Hedge M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015; 17:405–424. [PubMed: 25741868]
  28. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: Towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum Genet*. 2013; 132:1077–1130. [PubMed: 23820649]
  29. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Roesenthal EA, Kim DS, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP. Actionable, pathogenic incidental findings in 1,000 participants' exomes. *Am J Hum Genet*. 2013; 93:631–640. [PubMed: 24055113]
  30. Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Seung Kim D, Bennett JT, Crosslin DR, Ranchalis J, Jones KL, Rosenthal EA, Jarvik ER, Itsara A, Turner EH, Herman DS, Schleit J, Burt A, Jamal SM, Abrudan JL, Johnson AD, Conlin LK, Dulik MC, Santani A, Metterville DR, Kelly M, Foreman AKM, Lee K, Taylor KD, Guo X, Crooks K, Kiedrowski LA, Raffel LJ, Gordon O, Machini K, Desnick RJ, Biesecker LG, Lubitz SA, Mulchandani S, Cooper GM, Joffe S, Sue Richards C, Yang Y, Rotter JI, Rich SS, O'Donnell CJ, Berg JS, Spinner NB, Evans JP, Fullerton SM, Leppig KA, Bennett RL, Bird T, Sybert VP, Grady WM, Tabor HK, Kim JH, Bamshad MJ, Wilfond B, Motulsky AG, Ronald Scott

- C, Pritchard CC, Walsh TD, Burke W, Raskind WH, Byers P, Hisama FM, Rehm H, Nickerson DA, Jarvik GP. Actionable exomic incidental findings in 6503 participants: Challenges of variant classification. *Genome Res.* 2015; 25:305–315. [PubMed: 25637381]
31. Lawrence L, Sincan M, Markello T, Adams DR, Gill F, Godfrey R, Golas G, Groden C, Landis D, Nehrebecky M, Park G, Soldatos A, Tift C, Toro C, Wahl C, Wolfe L, Gahl WA, Boerkoel CF. The implications of familial incidental findings from exome sequencing: The NIH Undiagnosed Diseases Program experience. *Genet Med.* 2014; 16:741–750. [PubMed: 24784157]
  32. Jurgens J, Ling H, Hetrick K, Pugh E, Schiettecatte F, Doheny K, Hamosh A, Avramopoulos D, Valle D, Sobreira N. Assessment of incidental findings in 232 whole-exome sequences from the Baylor–Hopkins Center for Mendelian Genomics. *Genet Med.* 2015; 17:782–788. [PubMed: 25569433]
  33. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS. ClinGen, ClinGen—The Clinical Genome Resource. *N Engl J Med.* 2015; 372:2235–2242. [PubMed: 26014595]
  34. Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. *Health Aff.* 2008; 27:1600–1611.
  35. Evans JP, Berg JS, Olshan AF, Magnuson T, Rimer BK. We screen newborns, don't we?: Realizing the promise of public health genomics. *Genet Med.* 2013; 15:332–334. [PubMed: 23470837]
  36. Bick AG, Flannick J, Ito K, Cheng S, Vasani RS, Parfenov MG, Herman DS, DePalma SR, Gupta N, Gabriel SB, Funke BH, Rehm HL, Benjamin EJ, Aragam J, Taylor HA Jr, Fox ER, Newton-Cheh C, Kathiresan S, O'Donnell CJ, Wilson JG, Altshuler DM, Hirschhorn JN, Seidman JG, Seidman C. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. *Am J Hum Genet.* 2012; 91:513–519. [PubMed: 22958901]
  37. Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, Jula A, Lahermo P, Väänänen H, Toivonen L, Swan H, Viitasalo M, Nieminen MS, Peltonen L, Oikarinen L, Palotie A, Kontula K. High prevalence of four long QT syndrome founder mutations in the Finnish population. *Ann Med.* 2009; 41:234–240. [PubMed: 19160088]
  38. Lahtinen AM, Havulinna AS, Noseworthy PA, Jula A, Karhunen PJ, Perola M, Newton-Cheh C, Salomaa V, Kontula K. Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population. *Ann Med.* 2013; 45:328–335. [PubMed: 23651034]
  39. Van Driest SL, Wells QS, Stallings S, Bush WS, Gordon A, Nickerson DA, Kim JH, Crosslin DR, Jarvik GP, Carrell DS, Ralston JD, Larson EB, Bielinski SJ, Olson JE, Ye Z, Kullo IJ, Abul-Husn NS, Scott SA, Bottinger E, Almoguera B, Connolly J, Chiavacci R, Hakonarson H, Rasmussen-Torvik LJ, Pan V, Persell SD, Smith M, Chisholm RL, Kitchner TE, He MM, Brilliant MH, Wallace JR, Doheny KF, Shoemaker MB, Li R, Manolio TA, Callis TE, Macaya D, Williams MS, Carey D, Kapplinger JD, Ackerman MJ, Ritchie MD, Denny JC, Roden DM. Association of arrhythmia-related genetic variants with phenotypes documented in electronic medical records. *JAMA.* 2016; 315:47–57. [PubMed: 26746457]
  40. Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: Implications for personalized medicine. *J Clin Oncol.* 2013; 31:2554–2562. [PubMed: 23733757]
  41. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proc Natl Acad Sci USA.* 2014; 111:14205–14210. [PubMed: 25192939]
  42. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. *JAMA.* 2014; 312:1091–1092. [PubMed: 25198398]
  43. Flannick J, Beer NL, Bick AG, Agarwala V, Molnes J, Gupta N, Burt NP, Florez JC, Meigs JB, Taylor H, Lyssenko V, Irgens H, Fox E, Burslem F, Johansson S, Brosnan MJ, Trimmer JK, Newton-Cheh C, Tuomi T, Molven A, Wilson JG, O'Donnell CJ, Kathiresan S, Hirschhorn JN, Njølstad PR, Rolph T, Seidman JG, Gabriel S, Cox DR, Seidman CE, Groop L, Altshuler D. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. *Nat Genet.* 2013; 45:1380–1385. [PubMed: 24097065]
  44. Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, Brooks BP, Brownell I, Candotti F, Gonsalves SG, Hart SP, Kong HH, Rother KI, Sokolic R, Solomon BD, Zein WM, Cooper DN,

- Stenson PD, Mullikin JC, Biesecker LG. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. *Am J Hum Genet.* 2015; 96:913–925. [PubMed: 26046366]
45. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. *Nature.* 2014; 508:469–476. [PubMed: 24759409]
  46. Fabsitz RR, McGuire A, Sharp RR, Puggal M, Beskow LM, Biesecker LG, Bookman E, Burke W, Burchard EG, Church G, Clayton EW, Eckfeldt JH, Fernandez CV, Fisher R, Fullerton SM, Gabriel S, Gachupin F, James C, Jarvik GP, Kittles R, Leib JR, O'Donnell C, O'Rourke PP, Rodriguez LL, Schully SD, Shuldiner AR, Sze RKF, Thakuria JV, Wolf SM, Burke GL. Ethical and practical guidelines for reporting genetic research results to study participants: Updated guidelines from a National Heart, Lung, and Blood Institute working group. *Circ Cardiovasc Genet.* 2010; 3:574–580. [PubMed: 21156933]
  47. Jarvik GP, Amendola LM, Berg JS, Brothers K, Clayton EW, Chung W, Evans BJ, Evans JP, Fullerton SM, Gallego CJ, Garrison NA, Gray SW, Holm IA, Kullo IJ, Lehmann LS, McCarty C, Prows CA, Rehm HL, Sharp RR, Salama J, Sanderson S, VanDriest SL, Williams MS, Wolf SM, Wolf WA, eMERGE Act-ROR Committee and CERC Committee, CSER Act-ROR Working Group, Burke W. Return of genomic results to research participants: The floor, the ceiling, and the choices in between. *Am J Hum Genet.* 2014; 94:818–826. [PubMed: 24814192]
  48. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med.* 2015; 372:793–795. [PubMed: 25635347]
  49. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. *Prev Med.* 1975; 4:518–525. [PubMed: 1208363]
  50. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O'Donnell CJ, Vasani RS, Wolf PA, Levy D. The third generation cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, recruitment, and initial examination. *Am J Epidemiol.* 2007; 165:1328–1335. [PubMed: 17372189]
  51. Fuqua SR, Wyatt SB, Andrew ME, Sarpong DF, Henderson FR, Cunningham MF, Taylor HA Jr. Recruiting African-American research participation in the Jackson Heart Study: Methods, response rates, and sample description. *Ethn Dis.* 2005; 15(suppl. 6):S6-18–29.
  52. Wilson JG, Rotimi CN, Ekuwe L, Royal CD, Crump ME, Wyatt SB, Steffes MW, Adeyemo A, Zhou J, Taylor HA Jr, Jaquish C. Study design for genetic analysis in the Jackson Heart Study. *Ethn Dis.* 2005; 15(suppl. 6):S6-30–37.
  53. Keku E, Rosamond W, Taylor HA Jr, Garrison R, Wyatt SB, Richard M, Jenkins B, Reeves L, Sarpong D. Cardiovascular disease event classification in the Jackson Heart Study: Methods and procedures. *Ethn Dis.* 2005; 15(suppl. 6):S6-62–70.
  54. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM, Broad GO, Seattle GO, NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science.* 2012; 337:64–69. [PubMed: 22604720]
  55. Fisher S, Barry A, Abreu J, Minie B, Nolan J, Delorey TM, Young G, Fennell TJ, Allen A, Ambrogio L, Berlin AM, Blumenstiel B, Cibulskis K, Friedrich D, Johnson R, Juhn F, Reilly B, Shammass R, Stalker J, Sykes SM, Thompson J, Walsh J, Zimmer A, Zwirko Z, Gabriel S, Nicol R, Nusbaum C. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. *Genome Biol.* 2011; 12:R1. [PubMed: 21205303]
  56. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics.* 2009; 25:1754–1760. [PubMed: 19451168]
  57. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernysky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011; 43:491–498. [PubMed: 21478889]

58. Laros JFJ, Blavier A, den Dunnen JT, Taschner PEM. A formalized description of the standard human variant nomenclature in Extended Backus-Naur Form. *BMC Bioinformatics*. 2011; 12(suppl. 4):S5.
59. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics*. 2010; 26:2069–2070. [PubMed: 20562413]
60. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hinrichs AS, Learned K, Lee BT, Li CH, Raney BJ, Rhead B, Rosenbloom KR, Sloan CA, Speir ML, Zweig AS, Haussler D, Kuhn RM, Kent WJ. The UCSC Genome Browser database: 2014 update. *Nucleic Acids Res*. 2014; 42:D764–D770. [PubMed: 24270787]
61. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NST, Cooper DN. The Human Gene Mutation Database: 2008 update. *Genome Med*. 2009; 1:13. [PubMed: 19348700]
62. Aronson SJ, Clark EH, Babb LJ, Baxter S, Farwell LM, Funke BH, Hernandez AL, Joshi VA, Lyon E, Parthum AR, Russell FJ, Varugheese M, Venman TC, Rehm HL. The GeneInsight Suite: A platform to support laboratory and provider use of DNA-based genetic testing. *Hum Mutat*. 2011; 32:532–536. [PubMed: 21432942]
63. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: Public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res*. 2014; 42:D980–D985. [PubMed: 24234437]
64. Kreger BE, Splansky GL, Schatzkin A. The cancer experience in the Framingham Heart Study cohort. *Cancer*. 1991; 67:1–6. [PubMed: 1845934]
65. Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL. Metabolic dysregulation of the insulin–glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971–2008). *Cancer Epidemiol Biomarkers Prev*. 2013; 22:1825–1836. [PubMed: 24064521]
66. Sahai, H., Khurshid, A. *Statistics in Epidemiology: Methods, Techniques, and Applications*. CRC Press LLC; 1996. p. 352
67. Bertolini S, Pisciotto L, Rabacchi C, Cefalù AB, Noto D, Fasano T, Signori A, Fresa R, Aversa M, Calandra S. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. *Atherosclerosis*. 2013; 227:342–348. [PubMed: 23375686]
68. Fisher E, Scharnagl H, Hoffmann MM, Kusterer K, Wittmann D, Wieland H, Gross W, März W. Mutations in the apolipoprotein (apo) B-100 receptor-binding region: Detection of apo B-100 (Arg<sup>3500</sup>→Trp) associated with two new haplotypes and evidence that apo B-100 (Glu<sup>3405</sup>→Gln) diminishes receptor-mediated uptake of LDL. *Clin Chem*. 1999; 45:1026–1038. [PubMed: 10388479]
69. Garcia-Garcia A-B, Ivorra C, Martinez-Hervas S, Blesa S, Fuentes MJ, Puig O, Martín-de-Llano JJ, Carmena R, Real JT, Chaves FJ. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: Importance of genetic testing in the entire family. *Atherosclerosis*. 2011; 218:423–430. [PubMed: 21868016]
70. Liyanage KE, Hooper AJ, Defesche JC, Burnett JR, van Bockxmeer FM. High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. *Ann Clin Biochem*. 2008; 45:170–176. [PubMed: 18325181]
71. Norsworthy PJ, Vandrovцова J, Thomas ERA, Campbell A, Kerr SM, Biggs J, Game L, Soutar AK, Smith BH, Dominiczak AF, Porteous DJ, Morris AD, Generation Scotland. Aitman TJ. Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: A population-based study. *BMC Med Genet*. 2014; 15:70. [PubMed: 24956927]
72. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. *Proc Natl Acad Sci USA*. 1989; 86:587–591. [PubMed: 2563166]
73. Taylor A, Bayly G, Patel K, Yarram L, Williams M, Hamilton-Shield J, Humphries SE, Norbury G. A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100. *Ann Clin Biochem*. 2010; 47:487–490. [PubMed: 20736250]



74. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. *Cancer Res.* 2007; 67:4595–4604. [PubMed: 17510385]
75. Thompson BA, Spurdle AB, Plazzer J-P, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, Sart Ddu, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M. InSiGht, Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet.* 2014; 46:107–115. [PubMed: 24362816]
76. Choi J-O, Yu C-W, Chun Nah J, Rang Park J, Lee B-S, Jeong Choi Y, Cho B-R, Lee S-C, Woo Park S, Kimura A, Euy Park J. Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations. *Clin Cardiol.* 2010; 33:430–438. [PubMed: 20641121]
77. Lee WH, Hwang TH, Kimura A, Park SW, Satoh M, Nishi H, Harada H, Toyama J, Park JE. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. *Am Heart J.* 2001; 141:184–189. [PubMed: 11174330]
78. Murakami C, Nakamura S, Maeda K, Irie W, Oishi M, Sasaki C, Nakamura N, Kurihara K. Analysis of gene mutations encoding sarcomeric proteins in sudden death cases caused by cardiomyopathy. *Kitasato Med J.* 2014; 44:47–55.
79. Kazmierczak K, Paulino EC, Huang W, Muthu P, Liang J, Yuan CC, Rojas AI, Hare JM, Szczesna-Cordary D. Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy. *Am J Physiol Heart Circ Physiol.* 2013; 305:H575–H589. [PubMed: 23748425]
80. Lossie J, Ushakov DS, Ferenczi MA, Werner S, Keller S, Haase H, Morano I. Mutations of ventricular essential myosin light chain disturb myosin binding and sarcomeric sorting. *Cardiovasc Res.* 2012; 93:390–396. [PubMed: 22131351]
81. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG, Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature.* 2016; 536:285–291. [PubMed: 27535533]
82. Arbour L, Rezazadeh S, Eldstrom J, Weget-Simms G, Rupps R, Dyer Z, Tibbits G, Accili E, Casey B, Kmetc A, Sanatani S, Fedida D. A KCNQ1 V205M missense mutation causes a high rate of long QT syndrome in a First Nations community of northern British Columbia: A community-based approach to understanding the impact. *Genet Med.* 2008; 10:545–550. [PubMed: 18580685]
83. Jackson HA, McIntosh S, Whittome B, Asuri S, Casey B, Kerr C, Tang A, Arbour LT. LQTS in Northern BC: Homozygosity for KCNQ1 V205M presents with a more severe cardiac phenotype but with minimal impact on auditory function. *Clin Genet.* 2014; 86:85–90. [PubMed: 23844633]
84. National Heart Lung and Blood Institute (University of Washington, 2015).
85. Eldstrom J, Xu H, Werry D, Kang C, Loewen ME, Degenhardt A, Sanatani S, Tibbits GF, Sanders C, Fedida D. Mechanistic basis for LQT1 caused by S3 mutations in the KCNQ1 subunit of IKs. *J Gen Physiol.* 2010; 135:433–448. [PubMed: 20421371]
86. Winbo A, Stattin EL, Nordin C, Diamant UB, Persson J, Jensen SM, Rydberg A. Phenotype, origin and estimated prevalence of a common long QT syndrome mutation: A clinical, genealogical and molecular genetics study including Swedish R518X/KCNQ1 families. *BMC Cardiovasc Disord.* 2014; 14:22. [PubMed: 24552659]

87. Ehlermann P, Weichenhan D, Zehelein J, Steen H, Pribe R, Zeller R, Lehrke S, Zugck C, Ivandic BT, Katus HA. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. *BMC Med Genet.* 2008; 9:95. [PubMed: 18957093]
88. Kapplinger JD, Landstrom AP, Bos JM, Salisbury BA, Callis TE, Ackerman MJ. Distinguishing hypertrophic cardiomyopathy-associated mutations from background genetic noise. *J Cardiovasc Transl Res.* 2014; 7:347–361. [PubMed: 24510615]
89. Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: Disease expression in relation to age, gender, and long term outcome. *Circ Cardiovasc Genet.* 2012; 5:156–166. [PubMed: 22267749]
90. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2004; 44:1903–1910. [PubMed: 15519027]
91. Waldmüller S, Erdmann J, Binner P, Gelbrich G, Pankuweit S, Geier C, Timmermann B, Haremza J, Perrot A, Scheer S, Wachter R, Schulze-Waltrup N, Dermintzoglou A, Schönberger J, Zeh W, Jurmann B, Brodherr T, Börgel J, Farr M, Milting H, Blankenfeldt W, Reinhardt R, Özcelik C, Osterziel K-J, Loeffler M, Maisch B, Regitz-Zagrosek V, Schunkert H, Scheffold T, German Competence Network Heart Failure. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: Results from the German Competence Network Heart Failure. *Eur J Heart Failure.* 2011; 13:1185–1192.
92. Carballo S, Blair E, Watkins H. Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy. *Circulation.* 2005; 112:II-411.
93. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: Implications for genetic testing and counselling. *J Med Genet.* 2005; 42:e59. [PubMed: 16199542]
94. Kaski JP, Syrris P, Esteban MTT, Jenkins S, Pantazis A, Deanfield JE, McKenna WJ, Elliott PM. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. *Circ Cardiovasc Genet.* 2009; 2:436–441. [PubMed: 20031618]
95. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. *Circulation.* 2008; 118:1541–1549. [PubMed: 18809796]
96. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. *Circ Res.* 2009; 105:219–222. [PubMed: 19574547]
97. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burbani M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation.* 2003; 107:2227–2232. [PubMed: 12707239]
98. Saltzman AJ, Mancini-DiNardo D, Li C, Chung WK, Ho CY, Hurst S, Wynn J, Care M, Hamilton RM, Seidman GW, Gorham J, McDonough B, Sparks E, Seidman JG, Seidman CE, Rehm HL. Short communication: The cardiac myosin binding protein C Arg502Trp mutation: A common cause of hypertrophic cardiomyopathy. *Circ Res.* 2010; 106:1549–1552. [PubMed: 20378854]
99. Barahona-Dussault C, Benito B, Campuzano O, Iglesias A, Leung TL, Robb L, Talajic M, Brugada R. Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Clin Genet.* 2010; 77:37–48. [PubMed: 19863551]
100. Fressart V, Duthoit G, Donal E, Probst V, Deharo JC, Chevalier P, Klug D, Dubourg O, Delacretaz E, Cosnay P, Scanu P, Extramiana F, Keller D, Hidden-Lucet F, Simon F, Bessirard V, Roux-Buisson N, Hebert JL, Azarine A, Casset-Senon D, Rouzet F, Lecarpentier Y, Fontaine G, Coirault C, Frank R, Hainque B, Charron P. Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Spectrum of mutations and clinical impact in practice. *Europace.* 2010; 12:861–868. [PubMed: 20400443]

101. Baskin B, Skinner JR, Sanatani S, Terespolsky D, Krahn AD, Ray PN, Scherer SW, Hamilton RM. TMEM43 mutations associated with arrhythmogenic right ventricular cardiomyopathy in non-Newfoundland populations. *Hum Genet.* 2013; 132:1245–1252. [PubMed: 23812740]
102. den Haan AD, Tan BY, Zikusoka MN, Lladó LI, Jain R, Daly A, Tichnell C, James C, Amat-Alarcon N, Abraham T, Russell SD, Bluemke DA, Calkins H, Dalal D, Judge DP. Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Cardiovasc Genet.* 2009; 2:428–435. [PubMed: 20031617]
103. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, Ward D, Sen-Chowdhry S, Elliott PM, McKenna WJ. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: Impact of genetics and revised task force criteria. *Circulation.* 2011; 123:2701–2709. [PubMed: 21606390]
104. Syrris P, Ward D, Asimaki A, Sen-Chowdhry S, Ebrahim HY, Evans A, Hitomi N, Norman M, Pantazis A, Shaw AL, Elliott PM, McKenna WJ. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. *Circulation.* 2006; 113:356–364. [PubMed: 16415378]
105. Unsoeld B, Gunkel S, Vuoffo J, Pfeiffer C, Kranz A, Lossnitzer D, Wollnik B, Fabritz L, Fortmueller L, Paul M, Schulze-Bahr E, Kirchoff P, Hasenfuss G, Knoell R. Abstract 2291: Recapitulation of a right ventricular phenotype in a transgenic mouse model overexpressing the plakophilin-2 R413x mutation that causes severe ARVC in a large family. *Circulation.* 2009; 120:S168.
106. Berzina D, Nakazawa-Miklasevica M, Zestkova J, Aksenoka K, Irmejs A, Gardovskis A, Kalniete D, Gardovskis J, Miklasevics E. BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families. *BMC Med Genet.* 2013; 14:61. [PubMed: 23767878]
107. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brenner D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. *J Clin Oncol.* 1998; 16:2417–2425. [PubMed: 9667259]
108. Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: Implications on test strategies and clinical management. *Breast Cancer Res Treat.* 2012; 134:1229–1239. [PubMed: 22535016]
109. Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-alshiekh M, Bostrom B, Sencer S, D'Andrea AD. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. *Blood.* 2004; 103:2554–2559. [PubMed: 14670928]
110. Offit K, Levrán O, Mullaney B, Mah K, Nafa K, Batish SD, Diotti R, Schneider H, Deffenbaugh A, Scholl T, Proud VK, Robson M, Norton L, Ellis N, Hanenberg H, Auerbach AD. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *J Natl Cancer Inst.* 2003; 95:1548–1551. [PubMed: 14559878]
111. Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, Jayatilake H, Pritchard-Jones K, Stratton MR, Ridolfi-Luthy A, Rahman N, Breast Cancer Susceptibility Collaboration (UK). Familial Wilms Tumour Collaboration, Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. *J Med Genet.* 2005; 42:147–151. [PubMed: 15689453]
112. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. *Br J Cancer.* 2007; 97:826–831. [PubMed: 17700570]
113. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. *BMC Cancer.* 2008; 8:140. [PubMed: 18489799]

114. Novakovi S, Milatovi M, Cerkovnik P, Stegel V, Krajc M, Ho evar M, Žgajnar J, Vakselj A. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. *Int J Oncol.* 2012; 41:1619–1627. [PubMed: 22923021]
115. Pal T, Permeth-Wey J, Holtje T, Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. *Cancer Epidemiol Biomarkers Prev.* 2004; 13(Pt. 1):1794–1799. [PubMed: 15533909]
116. Edwards SM, Evans DGR, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA, UK Genetic Prostate Cancer Study Collaborators, BAUS Section of Oncology. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. *Br J Cancer.* 2010; 103:918–924. [PubMed: 20736950]
117. Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, Govindasami K, Guy M, Sawyer E, Wilkinson R, UKGPCS Collaborators. Antoniou AC, Eeles R, Kote-Jarai Z. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. *Br J Cancer.* 2014; 110:1663–1672. [PubMed: 24556621]
118. Plaschke J, Commer TS, Jacobi C, Schackert HK, Chang-Claude J. BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease. *J Med Genet.* 2000; 37:E17. [PubMed: 10978364]
119. Sh Kassem H, Azer RS, Saber-Ayad M, Moharem-Elgamal S, Magdy G, Elguindy A, Cecchi F, Olivotto I, Yacoub MH. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. *J Cardiovasc Transl Res.* 2013; 6:65–80. [PubMed: 23233322]
120. Laredo R, Monserrat L, Hermida-Prieto M, Fernández X, Rodríguez I, Cazón L, Alvaríño I, Dumont C, Piñón P, Peteiro J, Bouzas B, Castro-Beiras A. Beta-myosin heavy-chain gene mutations in patients with hypertrophic cardiomyopathy. *Rev Esp Cardiol.* 2006; 59:1008–1018. [PubMed: 17125710]
121. Moolman JC, Brink PA, Corfield VA. Identification of a novel Ala797Thr mutation in exon 21 of the  $\beta$ -myosin heavy chain gene in hypertrophic cardiomyopathy. *Hum Mutat.* 1995; 6:197–198. [PubMed: 7581410]
122. Moolman-Smook J, De Lange W, Corfield V, Brink P. Expression of HCM causing mutations: Lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation. *J Med Genet.* 2000; 37:951–956. [PubMed: 11186938]
123. Moolman-Smook JC, De Lange WJ, Bruwer EC, Brink PA, Corfield VA. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: A unique profile of both independent and founder events. *Am J Hum Genet.* 1999; 65:1308–1320. [PubMed: 10521296]
124. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ, Ackerman MJ. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2004; 44:602–610. [PubMed: 15358028]
125. Baumüller S, Herwig MC, Mangold E, Holz FC, Loeffler KU. Sebaceous gland carcinoma of the eyelid masquerading as a cutaneous horn in Li–Fraumeni syndrome. *Br J Ophthalmol.* 2011; 95:1470, 1478. [PubMed: 20693561]
126. Curry S, Ibrahim F, Grehan D, McDermott M, Capra M, Betts D, O'Sullivan M. Rhabdomyosarcoma-associated renal cell carcinoma: A link with constitutional Tp53 mutation. *Pediatr Dev Pathol.* 2011; 14:248–251. [PubMed: 21054160]
127. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG. The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nat Genet.* 2013; 45:242–252. [PubMed: 23334668]

128. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, Strong LC. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. *N Engl J Med.* 1992; 326:1309–1315. [PubMed: 1565144]
129. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber JE, Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. *Genet Med.* 2011; 13:651–657. [PubMed: 21552135]
130. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. *Cancer.* 2012; 118:908–913. [PubMed: 21761402]
131. Monti P, Ciribilli Y, Jordan J, Menichini P, Umbach DM, Resnick MA, Luzzatto L, Inga A, Fronza G. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. *Clin Cancer Res.* 2007; 13:3789–3795. [PubMed: 17606709]
132. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King M-C, Goodfellow P, Swisher EM. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. *Cancer.* 2013; 119:332–338. [PubMed: 22811390]
133. Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. *Clin Exp Metastasis.* 2007; 24:471–483. [PubMed: 17636407]
134. Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buginim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53<sup>R273H</sup> attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. *J Cell Sci.* 2012; 125:5578–5586. [PubMed: 22899716]
135. Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, Li H, Hu S, Weng Y, Yen Y. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. *Hum Mutat.* 2014; 35:575–584. [PubMed: 24677579]
136. Monti P, Perfumo C, Bisio A, Ciribilli Y, Menichini P, Russo D, Umbach DM, Resnick MA, Inga A, Fronza G. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. *Mol Cancer Res.* 2011; 9:271–279. [PubMed: 21343334]
137. Scian MJ, Stagliano KER, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Modulation of gene expression by tumor-derived p53 mutants. *Cancer Res.* 2004; 64:7447–7454. [PubMed: 15492269]
138. Wang W, Cheng B, Miao L, Mei Y, Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. *Cell Death Dis.* 2013; 4:e574. [PubMed: 23559009]
139. Zerdoumi Y, Aury-Landas J, Bonaïti-Pellié C, Derambure C, Sesboüé R, Renaux-Petel M, Frebourg T, Bougeard G, Flaman JM. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. *Hum Mutat.* 2013; 34:453–461. [PubMed: 23172776]
140. Sugawara W, Arai Y, Kasai F, Fujiwara Y, Haruta M, Hosaka R, Nishida K, Kurosumi M, Kobayashi Y, Akagi K, Kaneko Y. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. *Genes Chromosomes Cancer.* 2011; 50:535–545. [PubMed: 21484931]
141. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PPD, Goode EL. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. *Sci Rep.* 2014; 4:4026. [PubMed: 24504028]
142. Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. *Am J Hum Genet.* 1997; 60:1233–1236. [PubMed: 9150171]
143. Trujillano D, Weiss MER, Schneider J, Köster J, Papachristos EB, Saviouk V, Zakharkina T, Nahavandi N, Kovacevic L, Rolf A. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. *J Mol Diagn.* 2015; 17:162–170. [PubMed: 25556971]

144. Golmard L, Delnatte C, Laugé A, Moncoutier V, Lefol C, Abidallah K, Tenreiro H, Copigny F, Giraudeau M, Guy C, Barbaroux C, Amorim G, Briaux A, Guibert V, Tarabeux J, Caputo S, Collet A, Gesta P, Ingster O, Stern MH, Rouleau E, de Pauw A, Gauthier-Villars M, Buecher B, Bézieau S, Stoppa-Lyonnet D, Houdayer C. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. *Oncogene*. 2016; 35:1324–1327. [PubMed: 26028024]
145. Solano AR, Aceto GM, Delettieres D, Veschi S, Neuman MI, Alonso E, Chialina S, Chacón RD, Renato MC, Podestá EJ. BRCA1 and BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. *SpringerPlus*. 2012; 1:20. [PubMed: 23961350]
146. Soutar AK, Knight BL, Patel DD. Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors. *Proc Natl Acad Sci USA*. 1989; 86:4166–4170. [PubMed: 2726768]
147. Thormaehlen AS, Schuberth C, Won HH, Blattmann P, Joggerst-Thomalla B, Theiss S, Asselta R, Duga S, Merlini PA, Ardissino D, Lander ES, Gabriel S, Rader DJ, Peloso GM, Pepperkok R, Kathiresan S, Runz H. Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: A case for LDLR and myocardial infarction. *PLOS Genet*. 2015; 11:e1004855. [PubMed: 25647241]
148. Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V, Cozzolino S, Sorrentino V. Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. *J Med Genet*. 1999; 36:115–118. [PubMed: 10051009]
149. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test. *Hum Mol Genet*. 1999; 8:2055–2062. [PubMed: 10484775]
150. Carpenter D, Morris A, Robinson RL, Booms P, Iles D, Halsall PJ, Steele D, Hopkins PM, Shaw MA. Analysis of RYR1 haplotype profile in patients with malignant hyperthermia. *Ann Hum Genet*. 2009; 73:10–18. [PubMed: 18945287]
151. Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM. Genetic variation in RYR1 and malignant hyperthermia phenotypes. *Br J Anaesth*. 2009; 103:538–548. [PubMed: 19648156]
152. Girard T, Urwyler A, Censier K, Mueller CR, Zorzato F, Treves S. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. *Hum Mutat*. 2001; 18:357–358.
153. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJA, McCarthy TV. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. *Hum Mol Genet*. 1994; 3:1855–1858. [PubMed: 7849712]
154. Riazi S, Larach MG, Hu C, Wijesundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: Characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. *Anesth Analg*. 2014; 118:381–387. [PubMed: 23842196]
155. Tong J, Oyamada H, Demareux N, Grinstein S, McCarthy TV, MacLennan DH. Caffeine and halothane sensitivity of intracellular Ca<sup>2+</sup> release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. *J Biol Chem*. 1997; 272:26332–26339. [PubMed: 9334205]
156. Chao EC, Velasquez JL, Witherspoon MSL, Rozek LS, Peel D, Ng P, Gruber SB, Watson P, Rennett G, Anton-Culver H, Lynch H, Lipkin SM. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). *Hum Mutat*. 2008; 29:852–860. [PubMed: 18383312]
157. Cravo M, Afonso AJ, Lage P, Albuquerque C, Maia L, Lacerda C, Fidalgo P, Chaves P, Cruz C, Nobre-Leitao C. Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: Implications for genetic testing. *Gut*. 2002; 50:405–412. [PubMed: 11839723]
158. Lage PA, Albuquerque C, Sousa RG, Cravo ML, Salazar M, Francisco I, Maia L, Claro I, Suspiro A, Rodrigues P, Raposo H, Fidalgo PA, Nobre-Leitão C. Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma

- significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene. *Cancer*. 2004; 101:172–177. [PubMed: 15222003]
159. van der Zwaag PA, Jongbloed JDH, van den Berg MP, van der Smagt JJ, Jonbloed R, Bikker H, Hofstra RMW, van Tintelen JP. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Hum Mutat*. 2009; 30:1278–1283. [PubMed: 19569224]
160. Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, Bowser M, Harrison B, Aaron D, Mahanta LM, Lakdawala NK, McDermott G, White ET, Rehm HL, Lebo M, Funke BH. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. *Genet Med*. 2014; 16:601–608. [PubMed: 24503780]
161. Giudicessi JR, Ackerman MJ. Arrhythmia risk in long QT syndrome: Beyond the disease-causative mutation. *Circ Cardiovasc Genet*. 2013; 6:313–316. [PubMed: 23963159]
162. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AAM, Ackerman MJ. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION® long QT syndrome genetic test. *Heart Rhythm*. 2009; 6:1297–1303. [PubMed: 19716085]
163. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation*. 2000; 102:1178–1185. [PubMed: 10973849]
164. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: A common cause of severe long-QT syndrome. *Circulation*. 2004; 109:1834–1841. [PubMed: 15051636]
165. Giudicessi JR, Ackerman MJ. Prevalence and potential genetic determinants of sensorineural deafness in KCNQ1 homozygosity and compound heterozygosity. *Circ Cardiovasc Genet*. 2013; 6:193–200. [PubMed: 23392653]
166. Giudicessi JR, Kapplinger JD, Tester DJ, Alders M, Salisbury BA, Wilde AAM, Ackerman MJ. Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome. *Circ Cardiovasc Genet*. 2012; 5:519–528. [PubMed: 22949429]
167. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AAM, Ackerman MJ. Genetic testing for long-QT syndrome: Distinguishing pathogenic mutations from benign variants. *Circulation*. 2009; 120:1752–1760. [PubMed: 19841300]
168. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. *Heart Rhythm*. 2005; 2:507–517. [PubMed: 15840476]
169. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: Twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the  $\alpha$ -galactosidase A gene. *Hum Mol Genet*. 1994; 3:1795–1799. [PubMed: 7531540]
170. Gaggi M, Kain R, Jaksch P, Haider D, Mundigler G, Voigtlander T, Sunder-Plassmann R, Rommer P, Klepetko W, Sunder-Plassmann G. A single lung transplant in a patient with Fabry disease: Causality or far-fetched? A case report. *Case Rep Transplant*. 2013; 2013:905743. [PubMed: 23691425]
171. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ. Mutant  $\alpha$ -galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. *Biochem J*. 2007; 406:285–295. [PubMed: 17555407]

**Table 1**  
**Prespecified clinical features among sequenced participants**

SW, septal width; HR, heart rate; bpm, beats per minute; LV, left ventricle; RV, right ventricle; RA, right atrium; ECG, electrocardiogram.

Genes recommended by ACMG for return of secondary findings	RCFs for conditions associated with each gene
<i>APC, BRCA1, BRCA2, MEN1, MLH1, MSH2, MSH6, MUTYH, NF2, PMS2, PTEN, RB1, RET, SDHD, SDHAF2, SDHB, SDHC, STK11, TP53, TSC1, TSC2, VHL, WT1</i>	Previous diagnosis of cancer
<i>COL3A1, FBNI, TGFBR1, TGFBR2, SMAD3, ACTA2, MYLK, MYH11</i>	Echocardiography with aortic aneurysm (aortic root diameter >3.7 cm)
<i>MYBPC3, MYH7, TNNT2, TNNT3, TPM1, MYL3, ACTC1, PRKAG2, GLA, MYL2, LMNA</i>	Echocardiography with posterior LV, posterior wall thickness, or SW >12 mm, or echocardiography with LV diastolic diameter >6 cm and fractional shortening <20%
<i>RYR2</i>	HR >100 bpm
<i>PKP2, DSP, DSC2, TMEM43, DSG2</i>	Echocardiography with abnormal RV or RA appearance
<i>KCNQ1, KCNH2, SCN5A</i>	ECG with prolonged QT interval [QT >450 mm (in women) and QT >460 mm (in men)]
<i>LDLR, APOB, PCSK9</i>	Elevation of LDL >190 mg/dl on no cholesterol medications or elevation of LDL >130 mg/dl on cholesterol medications
<i>RYR1, CACNA1S</i>	No phenotype data available



Table 2

## Individuals with PVs and LPVs in the FHS

LOF, loss of function; F, female; M, male; PW, posterior wall width; LVD, left ventricular diameter; FS, fractional shortening; BC, breast cancer; OC, ovarian cancer; HCM, hypertrophic cardiomyopathy; HCL, hypercholesterolemia; ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Gene	Variant and amino acid	Amino acid	Summary of classification evidence*	Associated condition	RCFs	Age <sup>†</sup>	Sex
<b>PVs</b>							
<i>BRCA2</i>	c.5213_5216del	p.Thr1738Ilefs*2	Previously reported, LOF is a known mechanism of disease	BC; OC	Breast cancer	27–60	F
<i>BRCA2</i>	c.4398_4402del	p.Leu1466Phefs*2	Previously reported, LOF is a known mechanism of disease	BC; OC	Prostate cancer	48–75	M
<i>MYBPC3</i>	c.1504C>T	p.Arg502Trp	Well-established PV	HCM	SW, 1.03 cm PW, 1.07 cm LVD, 6.25 cm FS, 17%	41–71	M
<i>MYBPC3</i>	c.26-2A>G	p.?	Previously reported, some segregation, affects canonical splice site	HCM	Normal appearance of heart on echocardiography	38–73	M
<i>LDLR</i>	c.429C>A	p.Cys143*	Not previously reported, LOF is a known mechanism of disease	HCL	LDL, 195 mg/dl, on no cholesterol medication	35–68	F
<b>LPVs</b>							
<i>GLA</i>	c.335G>A	p.Arg112His	Previously reported in cases, limited segregation and functional evidence	Fabry	Normal appearance of heart on echocardiography	49–83	F
<i>DSP</i>	c.4180C>T	p.Gln1394*	Not previously reported, LOF is a suspected mechanism of disease	ARVD/C	Normal appearance of heart on echocardiography	24–58	F

\* Further details of classification evidence are provided in table S2.

<sup>†</sup> Ages followed in the FHS.

### Individuals with PVs and LPVs in the JHS

**Table 3**

CRC, colorectal carcinoma; MH, malignant hyperthermia; HPP, hypokalemic periodic paralysis; FDB, familial dysbetalipoproteinemia; HNPCC, hereditary nonpolyposis CRC; LQTS, long QT syndrome; IVS, interventricular septum; PWT, left ventricular posterior wall thickness; LFS, Li-Fraumeni syndrome; LVIDD, left ventricular internal diastolic diameter; NA, not analyzed, that is, individual was not included in the analysis because the expected phenotype was either unavailable (see Materials and Methods) or missing for the given individual.

Gene	Variant and amino acid	Amino acid	Summary of classification evidence*	Associated condition	RCFs	Age <sup>†</sup>	Sex
<b>PVs</b>							
<i>APOB</i>	c.10580G>A	p.Arg3527Gln	Well-established PV	FDB	LDL-C, 165 mg/dl	69	F
<i>MLH1</i>	c.2059C>T	p.Arg687Trp	Well-established PV	HNPCC	Cancer, 36	65	M
<i>SCN5A</i>	c.3214G>T	p.Glu1072*	Not previously reported, LOF is a known mechanism of disease	Brugada	NA	36	F
					NA	43	F
					NA	61	F
<i>MYL3</i>	c.170C>G	p.Ala57Gly	Well-established PV	HCM	IVS, 8.7 mm PWT, 7.4 mm	81	F
<i>KCNQ1</i>	c.613G>A	p.Val205Met	Previously reported, homozygosity associated with a more severe phenotype	LQTS	QTc, 477 ms	46	F
<i>KCNQ1</i>	c.1552C>T	p.Arg518*	Well-established PV, LOF is a known mechanism of disease	LQTS	QTc, 494 ms	63	F
<i>MYBPC3</i>	c.1504C>T	p.Arg502Trp	Well-established PV	HCM	IVS, 10.9 mm PWT, 7.8 mm	79	F
<i>PKP2</i>	c.1689-1G>C	p.?	Previously reported, LOF is a known mechanism of disease	ARVD/C	Normal RA/RV	49	M
<i>PKP2</i>	c.1237C>T	p.Arg413*	Previously reported, LOF is a known mechanism of disease	ARVD/C	Normal RA/RV	46	F
					Normal RA/RV	47	F
					NA	50	F
					Normal RA/RV	51	F

Gene	Variant and amino acid	Amino acid	Summary of classification evidence*	Associated condition	RCFs	Age <sup>†</sup>	Sex
					Normal RA/RV	72	F
					Normal RA/RV	74	F
					Normal RA/RV	74	F
<i>BRCA2</i>	c.658_659del	p.Val220Ilefs*4	Well-established PV, LOF is a known mechanism of disease	BC; OC	Cancer, 60	65	M
<i>BRCA2</i>	c.5611_5615del	p.Lys1872Asnfs*2	Previously reported, LOF is a known mechanism of disease	BC; OC	No cancer	39	F
<i>BRCA2</i>	c.5855T>A	p.Leu1952*	Not previously reported, LOF is a known mechanism of disease	BC; OC	No cancer	29	F
					No cancer	54	M
					No cancer	51	F
					No cancer	77	F
<i>BRCA2</i>	c.9382C>T	p.Arg3128*	Previously reported, LOF is a known mechanism of disease	BC; OC	No cancer	43	F
					No cancer	47	F
<i>MYN7</i>	c.2389G>A	p.Ala797Thr	Well-established PV	HCM	IVS, 13.2 mm PWT, 12.8 mm	66	M
<i>TP53</i>	c.818G>A	p.Arg273His	Well-established PV	LFS	Cancer, 89	93	M
<i>BRCA1</i>	c.5177_5180del	p.Arg1726fs*3	Previously reported, LOF is a known mechanism of disease	BC	No cancer	69	F
<i>BRCA1</i>	c.3607C>T	p.Arg1203*	Previously reported, Well-established PV, LOF is a known mechanism of disease	BC	No cancer	64	M
<i>LDLR</i>	c.2054C>T	p.Pro685Leu	Well-established PV	HCL	LDL-C, 358 mg/dl	36	M
<i>RYR1</i>	c.7300G>A	p.Gly2434Arg	Well-established PV	MH	NA	43	M
<b>LPVs</b>							
<i>MLHI</i>	c.1153C>T	p.Arg385Cys	Previously reported in cases, limited segregation and functional evidence	HNPCC	No cancer	36	M
<i>DSP</i>	c.3865C>T	p.Gln1289*	Not previously reported, heterogeneous expression of LOF mutations	ARVD/C	Normal RA/RV	66	M

Gene	Variant and amino acid	Amino acid	Summary of classification evidence*	Associated condition	RCFs	Age <sup>†</sup>	Sex
<i>KCNQ1</i>	c.535G>A	p.Gly179Ser	Previously reported in cases, limited segregation but supportive functional evidence	LQTS	QTc, 506 ms	69	F
<i>KCNQ1</i>	c.1085A>G	p.Lys362Arg	Previously reported in cases, limited segregation but supportive functional evidence	LQTS	QTc, 432 ms	57	F

\* Further details of classification evidence are provided in table S2.

<sup>†</sup> Age at exam 1, cancer phenotype is reported with age of diagnosis.

**Table 4**

Observed proportion of participants with PV or LPV who had RCFs of the associated condition compared to the expected proportion.

	Observed <sup>*</sup>	Expected <sup>†</sup>	SIR <sup>‡</sup>	P <sup>§</sup>
<b>Framingham Heart Study</b>				
All ACMG genes	4/5 (80.0%)	0.62/5 (12.4%)	6.4 (1.7–16.5)	$7 \times 10^{-4}$
Cancer	2/2 (100%)	0.15/2 (7.5%)	13.0 (1.5–47.0)	0.006
Cardiovascular	2/3 (66.7%)	0.46/3 (15.3%)	4.2 (0.5–15.4)	0.06
<b>Jackson Heart Study</b>				
All ACMG genes	7/26 (26.9%)	1.4/26 (5.4%)	4.7 (1.9–9.7)	$3 \times 10^{-4}$
Cancer	3/12 (25.0%)	0.7/12 (5.8%)	4.3 (0.9–12.6)	0.03
Cardiovascular	4/14 (28.6%)	0.8/14 (5.7%)	5.1 (1.4–12.0)	$4 \times 10^{-3}$

<sup>\*</sup> Observed fraction of individuals carrying a PV who had the associated RCF.

<sup>†</sup> Expected fraction of individuals based on the incidence of the RCF observed in individuals without PVs.

<sup>‡</sup> SIR and 95% CI.

<sup>§</sup> P values comparing observed and expected fraction of PV carriers with RCFs, calculated with a binomial simulation.